Cerebral FDG-PET scanning abnormalities in optimally treated HIV patients

Journal of Neuroinflammation

Volumn 7, Issue , 2010, Pages

  Andersen, Åse B ^a   Law, Ian ^a   Krabbe, Karen S ^a   Bruunsgaard, Helle ^a   Ostrowski, Sisse R ^a   Ullum, Henrik ^a   Højgaard, Liselotte ^a   Lebech, Annemette ^a   Gerstoft, Jan ^a   Kjær, Andreas ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; BRAIN DERIVED NEUROTROPHIC FACTOR; DIDANOSINE; FLUORODEOXYGLUCOSE F 18; INTERLEUKIN 6; STAVUDINE; TUMOR NECROSIS FACTOR ALPHA; UROKINASE RECEPTOR; CYTOKINE; DIAGNOSTIC AGENT;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; DEGENERATIVE DISEASE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE METABOLISM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; NEUROLOGIC DISEASE; POSITRON EMISSION TOMOGRAPHY; PREVALENCE; TREATMENT DURATION; VIRUS LOAD; BLOOD; BRAIN CORTEX; BRAIN MAPPING; METHODOLOGY; MIDDLE AGED; PATHOLOGY; SCINTISCANNING;

ADULT; AGED; BRAIN MAPPING; CEREBRAL CORTEX; CYTOKINES; FEMALE; FLUORODEOXYGLUCOSE F18; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY;

EID: 77950447514     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-7-13     Document Type: Article

References (29)

1. Price RW, Spudich S. Antiretroviral therapy and central nervous system HIV type 1 infection. J Infect Dis 2008, 197(Suppl 3):S294-S306. 10.1086/533419, 2628635, 18447615.
2. Brew BJ. Evidence for a change in AIDS dementia complex in the era of highly active antiretroviral therapy and the possibility of new forms of AIDS dementia complex. AIDS 2004, 18:S75-S78. 10.1097/00002030-200401001-00011, 15075501.
3. d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004, 55(3):320-328. 10.1002/ana.10827, 14991809.
4. Robinson-Papp J, Elliott KJ, Simpson DM. HIV-related neurocognitive impairment in the HAART era. Curr HIV/AIDSRep 2009, 6(3):146-152.
5. Antinori A, Arendt G, Becker JT, Brew BJ, Byrd DA, Cherner M, Clifford DB, Cinque P, Epstein LG, Goodkin K, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology 2007, 69(18):1789-1799. 10.1212/01.WNL.0000287431.88658.8b, 17914061.
6. Andersen AB, Law I, Ostrowski SR, Lebech AM, Hoyer-Hansen G, Hojgaard L, Gerstoft J, Ullum H, Kjaer A. Self-Reported Fatigue Common among Optimally Treated HIV Patients: No Correlation with Cerebral FDG-PET Scanning Abnormalities. Neuroimmunomodulation 2006, 13(2):69-75. 10.1159/000095222, 16926555.
7. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur J Nucl Med Mol Imaging 2005, 32(4):486-510. 10.1007/s00259-005-1762-7, 15747152.
8. Silverman DH. Brain 18F-FDG PET in the diagnosis of neurodegenerative dementias: comparison with perfusion SPECT and with clinical evaluations lacking nuclear imaging. J Nucl Med 2004, 45(4):594-607.
9. Bruunsgaard H. Effects of tumor necrosis factor-alpha and interleukin-6 in elderly populations. European CytokineNetwork 2002, 13(4):389-391.
10. Perry RT, Collins JS, Wiener H, Acton R, Go RC. The role of TNF and its receptors in Alzheimer's disease. Neurobiol Aging 2001, 22(6):873-883. 10.1016/S0197-4580(01)00291-3, 11754994.
11. Quan N, Herkenham M. Connecting cytokines and brain: A review of current issues. Histology and Histopathology 2002, 17(1):273-288.
12. Fumagalli F, Racagni G, Riva MA. The expanding role of BDNF: a therapeutic target for Alzheimer's disease?. Pharmacogenomics J 2006, 6(1):8-15. 10.1038/sj.tpj.6500337, 16314887.
13. Laske C, Stransky E, Leyhe T, Eschweiler GW, Wittorf A, Richartz E, Bartels M, Buchkremer G, Schott K. Stage-dependent BDNF serum concentrations in Alzheimer's disease. J Neural Transm 2006, 113(9):1217-1224. 10.1007/s00702-005-0397-y, 16362629.
14. Riisbro R, Piironen T, Brunner N, Larsen B, Nielsen HJ, Stephens RW, Hoyer-Hansen G. Measurement of soluble urokinase plasminogen activator receptor in serum. Journal of Clinical LigandAssay 2002, 25(1):53-56.
15. Riisbro R, Christensen IJ, Piironen T, Greenall M, Larsen B, Stephens RW, Han C, Hoyer-Hansen G, Smith K, Brunner N, et al. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer 8. Clin Cancer Res 2002, 8(5):1132-1141.
16. Lewellen TK, Kohlmyer SG, Miyaoka RS, Kaplan MS. Investigation of the performance of the general electric ADVANCE positron emission tomograph in 3D mode. Ieee Transactions on Nuclear Science 1996, 43(4):2199-2206.
17. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. JNucl Med 1995, 36(7):1238-1248.
18. Talairach J, Tournoux P. Co-planar stereotaxic atlas of the human brain. 1988, New York, Thieme Medical Publishers Inc.
19. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser 1995, 57:289-300.
20. Diehl-Schmid J, Grimmer T, Drzezga A, Bornschein S, Riemenschneider M, Forstl H, Schwaiger M, Kurz A. Decline of cerebral glucose metabolism in frontotemporal dementia: a longitudinal18F-FDG-PET-study. Neurobiol Aging 2007, 28(1):42-50. 10.1016/j.neurobiolaging.2005.11.002, 16448722.
21. Driver CB, Wallace DJ, Lee JC, Forbess CJ, Pourrabbani S, Minoshima S, Waxman AD, Weisman MH. Clinical validation of the watershed sign as a marker for neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 2008, 59(3):332-337. 10.1002/art.23308, 18311758.
22. Weaver JD, Huang MH, Albert M, Harris T, Rowe JW, Seeman TE. Interleukin-6 and risk of cognitive decline - MacArthur studies of successful aging. Neurology 2002, 59(3):371-378.
23. Cinque P, Nebuloni M, Santovito ML, Price RW, Gisslen M, Hagberg L, Bestetti A, Vago G, Lazzarin A, Blasi F, et al. The urokinase receptor is overexpressed in the AIDS dementia complex and other neurological manifestations. Ann Neurol 2004, 55(5):687-694. 10.1002/ana.20076, 15122709.
24. Sidenius N, Nebuloni M, Sala S, Zerbi P, Price RW, Gisslen M, Hagberg L, Vago L, Lazzarin A, Blasi F, et al. Expression of the urokinase plasminogen activator and its receptor in HIV-1-associated central nervous system disease. J Neuroimmunol 2004, 157(1-2):133-139. 10.1016/j.jneuroim.2004.08.038, 15579290.
25. Acquas E, Bachis A, Nosheny RL, Cernak I, Mocchetti I. Human immunodeficiency virus type 1 protein gp120 causes neuronal cell death in the rat brain by activating caspases. Neurotox Res 2004, 5(8):605-615. 10.1007/BF03033180, 15111237.
26. Bachis A, Aden SA, Nosheny RL, Andrews PM, Mocchetti I. Axonal transport of human immunodeficiency virus type 1 envelope protein glycoprotein 120 is found in association with neuronal apoptosis. J Neurosci 2006, 26(25):6771-6780. 10.1523/JNEUROSCI.1054-06.2006, 16793884.
27. von Giesen HJ, Antke C, Hefter H, Wenserski F, Seitz RJ, Arendt G. Potential time course of human immunodeficiency virus type 1-associated minor motor deficits: electrophysiologic and positron emission tomography findings. Arch Neurol 2000, 57(11):1601-1607. 10.1001/archneur.57.11.1601, 11074792.
28. Lin MT, Beal MF. Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases. Nature 2006, 443(7113):787-795. 10.1038/nature05292, 17051205.
29. Cardenas V, Meyerhoff D, Studholme C, Kornak J, Rothlind J, Lampiris H, Neuhaus J, Grant R, Chao L, Truran D, et al. Evidence for ongoing brain injury in human immunodeficiency virus-positive patients treated with antiretroviral therapy. J Neurovirol 2009, 1-10.